Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptome analysis of BMDCs treated with nanovesicle vaccines

ABSTRACT: Transcriptome analysis of BMDCs treated with nanovesicle vaccines

PROVIDER: PRJNA741932 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14930118_1.fastq.gz	Fastqsanger.gz
	SRR14930118_2.fastq.gz	Fastqsanger.gz
	SRR14930119.fastq.gz	Fastqsanger.gz
	SRR14930119_1.fastq.gz	Fastqsanger.gz
	SRR14930119_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 19

Similar Datasets

Transcriptome analysis of BMDCs treated with nanovesicle vaccines

Project description:We carried out in vitro transcriptome analysis of BMDCs treated with PEG-IM-MP and PEG-MP nanovesicles to understand the regulatory pathway of the immune response concerning gene expression.

2021-06-29 | GSE179021 | GEO

Intrinsic innate immunostimulation by small circRNA vaccines [BMDCs]

Project description:Intrinsic innate immunostimulation by small circRNA vaccines [BMDCs]

| PRJNA912723 | ENA

Next Generation Sequencing Facilitates Quantitative Analysis of Transcriptomes of BMDCs treated without or with exosomes from tumor cells or normal cells

Project description:The goals of this study are to compare the transcriptome profiling (RNA-seq) of tumor cell-derived exosome treated BMDCs to normal cell-derived exosome treaed BMDCs or untreated BMDCs to explore the differential regulated signaling pathways or cellular processes.

2021-01-04 | GSE155881 | GEO

Comparison between CD103+ cDC1s from IL-33-treated Flt3L-BMDCs and GM-CSF-treated Flt3L-BMDCs

Project description:Comparison between CD103+ cDC1s from IL-33-treated Flt3L-BMDCs and GM-CSF-treated Flt3L-BMDCs

| PRJNA940736 | ENA

Comparison between CD103+ cDC1s from IL-33-treated Flt3L-BMDCs and GM-CSF-treated Flt3L-BMDCs

Project description:To assess genotypic differences between IL-33-induced CD103+ cDC1s and GM-CSF-induced CD103+ cDC1s IL-33 or GM-CSF was treated at 5 ng/ml on the day 5 of Flt3L-BMDC generation and then the cells were incubated for an additional 5 days Then, we performed RNA sequencing of CD103+ cDC1s isolated from IL-33 or GM-CSF-treated Flt3L-BMDCs

2023-05-30 | GSE226585 | GEO

Gene expression profiles of mice BMDCs treated with Nitidine Chloride or vehicle following LPS stimulation

Project description:Nitidine Chloride(NC) were found to enhance IL-10 production in LPS-stimulated Bone-marrow dendritic cells(BMDCs ) ,while at the same time inhibit pro-inflammatory cytokines production, such as TNF- α and IL-6. BMDCs were treated with NC or vehicle following LPS stimulation to find out the influence of NC on BMDCs that regulate cytokines expression. This study indicated that NC regulate numerous gene expression, thus influence IL-10 and pro-inflammatory cytokines production in LPS-treated BMDCs.

2017-08-05 | GSE102135 | GEO

Transcriptome analysis of total blood cells from sheep after vaccination with FMDV vaccines

Project description:Transcriptome analysis of total blood cells from sheep collected at 0, 4 and 24 hours after vaccination with inactivated FMDV vaccine, and adenovirus (human Ad5)-based vaccines encoding FMDV antigens, with and without Montanide ISA206 VG adjuvant.

2019-12-10 | GSE135609 | GEO

small RNAseq in donor BMDCs and BMDCs that received exosomes

Project description:small RNAseq was preformed on Wt bone marrow-derived dendritic cells (BMDC) and miR-155 and miR-146a double knockout (DKO) BMDCs that received Wt exosomes to investigate the differences in transferred miRNA Small RNA profiles were generated from Wt donor BMDCs and DKO BMDCs given Wt exosomes 3 replicates in each group

2016-07-03 | E-GEOD-67946 | biostudies-arrayexpress

Synthetic self-adjuvanted lipopeptide vaccines conferred protection against Helicobacter pylori infection

Project description:Helicobacter pylori (H. pylori) colonize the stomach epithelium of half the world's population and are responsible for a variety of digestive diseases and even stomach cancer. The protection against H. pylori infection depends primarily on the antigen-mediated mucosal and T cell responses. We hypothesized that lipopeptide vaccines obtained by covalently conjugation of Pam2Cys with strong mucosal adjuvant activity to the immunodominant epitope from protective antigens could induce protective responses against H. pylori infection. In this study, the synthetic lipopeptide vaccines, Hp4 (Pam2Cys modified UreB T cell epitope) and Hp10 (Pam2Cys modified CagA T/B cell combined epitope), induced the BMDCs maturation in vitro by activating a variety of pattern recognition receptors such as TLR, NLR and RLR. In addition, lipopeptide vaccines stimulated BMDCs to secret cytokines that have the potential to modulate T cell activation and differentiation. Although intranasal immunization with Hp4 or Hp10 elicited robust epitope-specific T cell responses in mice, only Hp10 conferred protection against H. pylori infection, possibly due to the fact that Hp10 also induced substantial specific sIgA response at mucosal sites. Interestingly, when two lipopeptide vaccines were administrated in combination, Hp4 elevated the protective response against H. pylori infection of Hp10, which was characterized by better protective effect and enhanced specific T cell and mucosal antibody responses. Our results suggest that synthetic lipopeptide vaccines based on the epitopes derived from the protective antigens are promising candidates for protection against H. pylori infection.

2023-01-01 | GSE218459 | GEO

Analysis of fucoidan-induced global transcriptional changes in bone marrow-derived dendritic cells (BMDCs) using RNA-Seq technology

Project description:To investigate the fucoidan-induced global change of signal transduction pathways, we prepared the bone marrow-derived dendritic cells (BMDCs) and treated them with fucoidan. We then performed gene expression profiling analysis using data obtained from RNA-seq of 6 different cells at one time point.

2022-04-21 | GSE200944 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data